A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for Systemically Constraining Hepatocellular Carcinoma
ACS Nano · 2023
DOI: 10.1021/acsnano.3c08064 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2023. Verfasst von Zhou Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Radiofrequency Ablation. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Primary Research and Development Plan of Zhejiang Province, National Natural Science Foundation of China, Jinhua Science and Technology Bureau.
Abstract (Originalsprache)
Radiofrequency ablation (RFA) is one of the most common minimally invasive techniques for treating hepatocellular carcinoma (HCC), which could destroy tumors through hyperthermia and generate massive tumor-associated antigens (TAAs). However, residual malignant tissues or small satellite lesions are hard to eliminate, generally resulting in metastases and recurrence. Herein, an advanced in situ nanovaccine formed by layered double hydroxides carrying cGAMP (STING agonist) (LDHs-cGAMP) and adsorbed TAAs was designed to potentiate the RFA-induced antitumor immune response. As-prepared LDHs-cGAMP could effectively enter cancerous or immune cells, inducing a stronger type I interferon (IFN-I) response. After further adsorption of TAAs, nanovaccine generated sustained immune stimulation and efficiently promoted activation of dendritic cells (DCs). Notably, infiltrations of cytotoxic lymphocytes (CTLs) and activated DCs in tumor and lymph nodes were significantly enhanced after nanovaccine treatment, which distinctly inhibited primary, distant, and metastasis of liver cancer. Furthermore, such a nanovaccine strategy greatly changed the tumor immune microenvironment and promoted the response efficiency of anti-programmed death ligand 1 (αPD-L1) immunotherapy, significantly arresting the poorly immunogenic hepa1-6 liver cancer progression. These findings demonstrate the potential of nanovaccine as a booster for RFA in liver cancer therapy and provide a promising in situ cancer vaccination strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China.
- Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China.
- Department of Ultrasonography, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China.
- Department of Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, Zhejiang 310000, China.
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China.
- International Institutes of Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, China.
ORCID-Profile: Zhou Tian, Weiyu Chen
Förderung
- Primary Research and Development Plan of Zhejiang Province
- National Natural Science Foundation of China
- Jinhua Science and Technology Bureau
- Natural Science Foundation of Zhejiang Province
- Huadong Medicine
Zitieren
APA
Tian, Z., Hu, Q., Sun, Z., Wang, N., He, H., Tang, Z., & Chen, W. (2023). A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for Systemically Constraining Hepatocellular Carcinoma. ACS Nano. https://doi.org/10.1021/acsnano.3c08064
Vancouver
Tian Z, Hu Q, Sun Z, Wang N, He H, Tang Z, et al. A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for Systemically Constraining Hepatocellular Carcinoma. ACS Nano. 2023. doi:10.1021/acsnano.3c08064
BibTeX
@article{Tian2023,
author = {Tian, Zhou and Hu, Qitao and Sun, Zhouyi and Wang, Ning and He, Huiling and Tang, Zhe and Chen, Weiyu},
title = {A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for Systemically Constraining Hepatocellular Carcinoma},
journal = {ACS Nano},
year = {2023},
doi = {10.1021/acsnano.3c08064}
}
EUVIMED